drugset / Trial / NCT03175978
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the safety and tolerability of utilizing the insulin-like growth factor-1-methotrexate conjugate, 765IGF-MTX for the treatment of advanced, previously treated myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and oligoblastic acute myelogenous leukemia (oligoblastic AML or O-AML), including determining the maximum tolerated dose (MTD).
Timeline
- Start
- 2018-02-21
- Primary completion
- 2021-06-30
- Completion
- 2021-09-30
Outcome
Outcome not reported
Stopped (Business): “Funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 765IGF-MTX | Other / unclassified | 0.2 unknown | Intravenous |
| Subject | 765IGF-MTX | Other / unclassified | 2.5 unknown | Intravenous |